Research Will Detail New Diabetes Kidney Therapy
New clinical and laboratory findings on the treatment rilparencel will be presented to medical experts this October.
Updated on Oct. 2, 2026 in Diabetes
Live Poll
Will upcoming kidney research presentations provide clear evidence of real-world patient benefit?
ProKidney is set to present eight research abstracts detailing its investigational drug rilparencel at the American Society of Nephrology's Kidney Week in Denver, occurring October 21-25, 2026. The findings offer new insights for patients with advanced chronic kidney disease and type 2 diabetes.
Why it matters
These presentations provide deeper insight into how rilparencel may work to potentially stabilize kidney function in those with advanced disease. The analysis serves to validate the therapeutic approach as the company moves toward later-stage clinical research.
The evidence includes data from seven translational model studies and one pooled Phase 2 clinical analysis. The findings represent preliminary evidence on the drug's mechanism of action and its observed effect on kidney function in patients with advanced CKD and type 2 diabetes.
The players
ProKidney
A biotechnology company focused on developing cell-based regenerative therapies for chronic kidney disease.
American Society of Nephrology
A professional organization for kidney specialists that provides education and sets clinical standards for nephrology care.
The details
Rilparencel is designed to address the complex biological decline seen in advanced chronic kidney disease. The upcoming presentations will explore the multifactorial mechanism of the drug candidate, which was evaluated for its ability to stabilize kidney function during Phase 2 testing. ProKidney used these earlier study results to identify specific patient characteristics that will guide the focus of ongoing Phase 3 clinical trials.
Timeline
October 21-25, 2026: American Society of Nephrology Kidney Week conference.
October 22, 2026: Two poster presentations on the research.
October 23, 2026: One oral presentation and two poster sessions.
October 24, 2026: Three additional poster presentations.
Health Landscape
The release of this data occurs within the broader landscape of regenerative medicine research for patients with type 2 diabetes and advanced CKD. It signals a shift in the standard of care as researchers move from basic translational models toward defining outcomes for Phase 3 evaluation.
Patients with advanced kidney disease and type 2 diabetes should discuss the current standard of care and emerging research options with their nephrologist to understand if they may be candidates for future clinical trials. It is important to wait for formal publication of results from Phase 3 studies before weighing the potential benefits of new, unapproved therapies.
The takeaway
While these preliminary results offer a promising look at how a new drug may preserve kidney function, they remain in the investigative phase. Readers should continue to monitor their kidney health metrics closely with their physician and follow established protocols for managing diabetic kidney disease.
Further reading
Learn more about the latest breakthroughs in managing blood sugar and organ health in our Diabetes section.
More information
Review the full list of scientific findings at the ASN Kidney Week abstract search.
Live Poll
Will upcoming kidney research presentations provide clear evidence of real-world patient benefit?
